These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35898250)

  • 1. Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb.
    Booth JP; Pilz J
    Hosp Pharm; 2022 Aug; 57(4):455-461. PubMed ID: 35898250
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb).
    Jin R; Ogbomo AS; Accortt NA; Lal LS; Bishi G; Sandschafer D; Goldschmidt JH
    Ther Adv Med Oncol; 2023; 15():17588359231182386. PubMed ID: 37360769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer.
    Pham C; Niu F; Delate T; Buchschacher GL; Li Y; Ekinci E; Le K; Hui RL
    BioDrugs; 2023 Nov; 37(6):891-899. PubMed ID: 37747629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US.
    Jin R; Mahtani RL; Accortt N; Lawrence T; Sandschafer D; Loaiza-Bonilla A
    Ther Adv Med Oncol; 2021; 13():17588359211041961. PubMed ID: 35003333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer.
    Rhodes W; DeClue RW; Accortt NA; Jin R; Sandschafer D; Wertz D; Patel K
    Future Oncol; 2021 Dec; 17(36):5119-5127. PubMed ID: 34698523
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA's Approval of the First Biosimilar to Bevacizumab.
    Casak SJ; Lemery SJ; Chung J; Fuchs C; Schrieber SJ; Chow ECY; Yuan W; Rodriguez L; Gwise T; Rowzee A; Lim S; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2018 Sep; 24(18):4365-4370. PubMed ID: 29743182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.
    Xue X; Qian J
    Expert Opin Drug Saf; 2024 May; ():1-10. PubMed ID: 38680112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
    Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
    BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars as a Future, Promising Solution for Financial Toxicity: A Review with Emphasis on Bevacizumab.
    Saleem T; Qurashi H; Jamali M; Chan Gomez J; Kanderi T
    Cureus; 2020 Jul; 12(7):e9300. PubMed ID: 32832297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data.
    Lu B; Dvorani E; Nguyen L; Beca JM; Mercer RE; Adamic A; Muñoz C; Chan KKW
    Value Health; 2024 Dec; 27(12):1689-1697. PubMed ID: 39127249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab safety in Japanese patients with colorectal cancer.
    Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
    Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
    Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
    J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative cost savings of biosimilar and dose rounding utilization in oncology care.
    Abdelmeseh V; Brown BR; Huynh JP; Zullo AR
    J Oncol Pharm Pract; 2023 Sep; 29(6):1437-1442. PubMed ID: 36259235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.